Tudor Investment Corp
MPLT

Tudor Investment Corp’s MapLight Therapeutics MPLT Stock Holding History

Tudor Investment Corp’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$747K Sell
36,740
-11,100
-23% -$199K ﹤0.01% 2567
2025
Q4 		$840K Buy
+47,840
New +$802K ﹤0.01% 2392

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tudor Investment Corp's MPLT Position: Q1 2026 in Review

Tudor Investment Corp reduced its MapLight Therapeutics (MPLT) stake by 23% in Q1 2026, selling an estimated $199K and leaving 36,740 shares worth $747K. The position accounts for ﹤0.01% of the portfolio, ranked #2567.

Tudor Investment Corp first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. The position peaked at $840K in Q4 2025. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Tudor Investment Corp held 36,740 shares of MapLight Therapeutics worth $747K as of Q1 2026.
  • Tudor Investment Corp sold 11,100 MapLight Therapeutics shares in Q1 2026, an estimated $199K.
  • MapLight Therapeutics made up ﹤0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #2567 holding.
  • Tudor Investment Corp first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Tudor Investment Corp's MapLight Therapeutics position peaked at $840K in Q4 2025.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.